Avenue Therapeutics raises $4.4M via warrant exercise inducement; issues new warrants

On April 28, 2024, Avenue Therapeutics, Inc. (the “ Company ”) entered into inducement offer letter agreements (the “ Inducement Letters ”) with (i) certain investors (the “ October 2022 Investors ”) that hold certain outstanding warrants to purchase up to an aggregate of 27,271 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), originally issued to the October 2022 Investors on October 11, 2022 (the “ October 2022 Warrants ”); (ii) certain investors (the “ November 2023 Investors ”) that hold certain outstanding Series A and Series B warrants to purchase up to an aggregate of 221,333 shares of Common Stock, originally issued to the November 2023 Investors on October 31, 2023 (the “ November 2023 Warrants ”); and (iii) certain investors (the “ January 2024 Investors ” and, collectively with the October 2022 Investors and November 2023 Investors, the “ Holders ”) that hold certain outstanding Series A and Series B warrants to purchase up to an agg